Kooperativer Bibliotheksverbund

UID:

Umfang: 1 online resource (443 pages)

Ausgabe: 1st ed.

ISBN: 9780443151798 , 0443151792

Inhalt: This book, 'Advances in Antiparasitic Therapies and Drug Delivery,' edited by Prashant Kesharwani and Neelima Gupta, provides a comprehensive exploration of recent developments in antiparasitic treatments and drug delivery systems. It covers a wide range of topics including traditional medicine, nanomedicine, and novel drug delivery methods such as microneedles and nanoemulsions. The text discusses challenges in treating parasitic infections, with a focus on malaria, and offers insights into the potential repurposing of antiparasitic drugs for other diseases. Additionally, it addresses issues of antimicrobial resistance and introduces emerging concepts like aptamers for managing parasitic diseases. Designed for researchers and healthcare professionals, the book aims to enhance understanding and advancement in the field of antiparasitic therapy.

Anmerkung: Front Cover -- Advances in Antiparasitic Therapies and Drug Delivery -- Copyright Page -- Contents -- List of contributors -- 1 An introduction to the pathophysiology of parasitic infection -- Introduction -- Parasitic infections -- Malaria -- Leishmaniasis -- Filariasis -- Onchocerciasis (River Blindness) -- Ascariasis, hookworm infection, and trichuriasis -- Toxoplasmosis -- Amebic meningoencephalitis -- Granulomatous amebic encephalitis -- Other parasitic infections -- Schistosomiasis -- Amebiasis -- Blastocystis hominis -- Giardiasis -- Conclusion -- Acknowledgment -- Declarations of Interest -- Funding -- References -- 2 Traditional medicine and natural products as antiparasitic agents -- Abbreviation -- Introduction -- Human parasitic diseases -- Alkaloids -- Quinine and related compounds -- Emetine and related compounds -- Indole alkaloids -- Isoquinoline alkaloids -- Benzoquinolizidine and naphthylisoquinoline alkaloids -- Acridone alkaloids -- Steroidal alkaloids -- Miscellaneous alkaloids -- Diterpene alkaloids -- Essential oils -- Quinones -- Phenolics -- Terpenes -- Antiplasmodial terpenes -- Terpenes mechanism against Plasmodium falciparum -- Terpenes -- Iridoids and monoterpenes -- Sesquiterpenes -- Diterpenes -- Tetranorditerpenes -- Terpenoid Benzoquinones and Analogs -- Steroids -- Quassinoids -- Limonoids -- Cucurbitacins -- Lanostanes -- Other triterpenes -- Miscellaneous compounds -- Diterpene-benzoate macrolides and analogs -- Cannabis in malaria -- Schistosomicidal terpenes -- Terpenes mechanism against Schistosoma -- Anthelmintic activity of terpenes -- Terpenes against trichomonas vaginalis -- Terpenes against trypanosomes (trypanosoma and leishmania) -- Trypanomiasis -- Terpenes in trypanosoma -- Antitrypanosomal activities and cytotoxicities of monterpenes. , Antitrypanosomal activities and cytotoxicities of sesquiterpenes -- Antitrypanosomal activities and cytotoxicities of diterpenes -- Leishmaniasis -- Terpenes in leishmaniasis -- Terpenes mechanism against schistosoma -- Green nanoparticles as antiparasitic agents -- Conclusion -- References -- 3 Antiparasitic drugs: a definition and scope -- Introduction -- Antiprotozoal agents -- Antimalarials -- Antibabesial agents -- Antiamebic agents -- Antigiardial agents -- Trypanocidal agents -- Antileishmanial agents -- Anti-toxoplasma agents -- Antitrichomoniasis agents -- Antihelminthic agents -- Ectoparasiticides -- References -- 4 Ectoparasitic and endoparasitic drug delivery approaches for therapy -- Introduction -- Chiggers -- Bed bugs -- Lice -- Scabies -- Demodex -- Controlled drug delivery systems -- Hydrogel -- Microspheres -- Microemulsion -- Nanoemulgel -- Discussion and conclusion -- References -- 5 Microneedles in antiparasitic drug delivery applications -- Introduction -- Overview of antiparasitic drugs and challenges -- Approaches to overcome the challenges -- Microneedles comprising antiparasitic medications -- Discussion and conclusion -- References -- 6 Nanotechnology: an approach to faster diagnosis of parasitic infections -- Introduction -- Ectoparasites -- Helminth parasites -- Protozoan parasite -- Correlation of nanotechnology and parasitic-induced diseases diagnosis: current and future perspectives -- Conclusion -- Acknowledgment -- Declarations of Interest -- Funding -- Author Contributions -- Reference -- 7 Nanomedicine for parasitic helminth infections -- Abbreviations -- Introduction -- A brief overview through helminth and parasitic worms -- Current anthelmintics-soil-transmitted helminth -- Current anthelmintics-schistosomiasis -- Current anthelmintics-lymphatic filariasis -- Current anthelmintics-onchocerciasis. , Anthelmintic/nanotechnology and nanomedicine -- Albendazole nanocrystals -- Gold nanoparticles -- Zinc oxide and iron oxide nanoparticles -- Polyaniline-coated silver nanoparticles of momordica charantia extract -- Nanovaccines -- Conclusion -- References -- 8 Pathogenesis, treatments, and challenges associated with malaria and nanomedicines for antimalarial therapy -- Abbreviations -- Introduction -- Pathogenesis of malaria -- Cerebral malaria -- Sever malaria anemia -- Malaria-associated acute respiratory distress syndrome -- Current treatment options for malaria -- Challenges in malaria management -- Nanomedicines for antimalarial therapy -- Conclusion -- References -- 9 Repurposing antiparasitic drugs for the treatment of other diseases -- Introduction -- Search methods -- Antiparasitic drug -- kinds of pharmacological aspect -- Anthelmintic drugs -- Drugs effective on nematodes -- Ivermectin -- Albendazole and mebendazole -- Diethylcarbamazine -- Drugs effective on trematodes -- Praziquantel -- Bithionol -- Metrifonate -- Oxamniquine -- Drugs effective on cestodes -- Niclosamide -- Antiprotozoal drugs -- Quinine -- Chloroquine -- Artemisinin -- Mefloquine -- Primaquine -- Antifungal drugs -- Amphotericin B -- Azoles -- Flucytosine -- Echinocandins -- Griseofulvin -- Allylamines -- Antiparasitic drugs -- antiinflammatory properties -- Ivermectin -- Mebendazole -- Albendazole -- Diethylcarbamazine -- Praziquantel -- Chloroquine and hydroxychloroquine -- Evidences of antiparasitic drugs in the treatment of inflammatory disease -- COVID-19 -- IVC -- Quinacrine -- Cancer -- Pyrvinium pamoate -- Niclosamide -- Mebendazole -- Albendazole -- Levamisole -- IVC -- Praziquantel -- Quinacrine -- Pentamidine -- Kidney diseases -- Levamisole -- Niclosamide -- Pneumonia -- Diabetes -- Gastrointestinal diseases -- Mebendazole -- Niclosamide -- Pentamidine. , Quinacrine -- Cardiac diseases -- Pentamidine -- P. pamoate -- Other diseases -- Levamisole -- Conclusion -- References -- 10 Marketed antiparasitic nanotechnology-based products and drawbacks -- Abbreviations -- Introduction -- Method of research -- Nanotechnology-based products -- Fungizone -- Abelcet -- AmBisome -- Amphotec -- Challenges of antiparasitic products based on nanotechnology -- Regulatory concerns -- Developmental and manufacturing cost -- Scale-up issues -- Conclusion -- Acknowledgment -- Funding -- Declarations of interest -- References -- 11 Fighting parasites during the post-antibiotic era -- Introduction -- Method of research -- Antibiotic therapy of parasitic infections -- Novel treatments of parasitic infections post-antibiotics -- Plants -- Nanotechnology -- Conclusion and future perspectives -- Funding -- References -- 12 Antimicrobial resistance and recent advancement to combat parasitic infections -- development of resistance to antihelmint... -- Antiparasitic control agents -- Therapeutic agents and resistance in Plasmodium species -- Development of resistance in Plasmodium falciparum -- Antiparasitic agents for amebiasis and other parasites -- Chemotherapeutic agents against Leishmaniasis -- Resistance against antiparasitic agents in other parasites -- Chemotherapeutic agents against trypanosomes (Table 12.5) -- Chemotherapeutic agents against fascioliasis and other parasites -- Resistance development to antiparasitic agents -- The emergence of resistance toward antiparasitic agents -- Selection pressure of the drug -- Mutations, life cycle, and susceptibility of the stage of the parasite for drug therapy -- Factors related to antiparasitic agents -- Ecological and geographical factors -- Drug pressure -- Refugia parasites -- Competition or fitness -- Mechanism of action of the antiparasitic agent. , Evading the action of the drugs -- Measures to combat antiparasitic resistance -- References -- 13 Aptamers as an emerging concept for the management of parasitic diseases -- Introduction -- Vaccines development and challenges -- Aptamers as promising tools -- Identification of aptamers -- SELEX technology -- Modification of production processes of aptamers for augmenting production or efficacy -- Increasing efficacy of the aptamers -- Monoclonal antibodies versus aptamers -- Peptide aptamers or "peptamers" -- Applications of aptamers -- Aptamers find wide applications in diagnosis, proteomics, pathology, cell sorting, and affinity purification -- Aptamers for targeted delivery -- Aptamers in cancer diagnosis -- Therapy using aptamers -- Aptamers in parasitic diseases -- Aptamers targeting Plasmodium spp -- Aptamers targeting Entamoeba histolytica -- Aptamers targeting Trypanosoma species -- Aptamers targeting Leishmania species -- Aptamers targeting Cryptosporidium parvuum -- Limitations and challenges of aptamers -- References -- 14 Where do we stand? Insight on patented products and those under clinical trials -- Introduction -- Search methods -- Novel antiparasitic drug properties -- Liposomes -- Solid lipid nanoparticles -- Nanostructured lipid carriers -- Polymeric micro- and nanoparticles -- Nanoemulsion and nanocapsule -- Nanosuspension -- Nanoparticles toxicity and safety -- Recent clinical trial on antiparasitics drugs -- Tricobendazole -- Albendazole -- Mebendazole -- Moxidectin -- Benznidazole -- Tafenoquine -- Miltefosine -- Nitazoxanide -- Recent FDA-approved drugs -- what are their features? -- Tricobendazole -- Albendazole and mebendazole -- Moxidection -- Benznidazole -- Tafenoquine -- Miltefosine -- Artemether-lumefantrine -- Nitazoxanide -- Consideration of future antiparasitic drugs -- Conclusion -- References. , 15 Challenges and opportunities in antiparasitic drug discovery and delivery.

Weitere Ausg.: ISBN 9780443151781

Sprache: Englisch